Insider Selling: Xencor, Inc. (NASDAQ:XNCR) VP Sells 68,684 Shares of Stock

Xencor, Inc. (NASDAQ:XNCR) VP John R. Desjarlais sold 68,684 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the completion of the sale, the vice president now owns 200,104 shares of the company’s stock, valued at $4,698,441.92. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Xencor Stock Performance

NASDAQ XNCR opened at $23.61 on Thursday. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average of $20.84 and a 200-day moving average of $20.37. Xencor, Inc. has a 12 month low of $15.31 and a 12 month high of $26.84.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27. The business had revenue of $10.70 million during the quarter, compared to analyst estimates of $14.59 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business’s revenue was down 81.9% on a year-over-year basis. During the same period last year, the business earned ($0.40) EPS. On average, analysts anticipate that Xencor, Inc. will post -3.79 earnings per share for the current year.

Institutional Investors Weigh In On Xencor

A number of institutional investors have recently made changes to their positions in XNCR. Darwin Global Management Ltd. acquired a new position in Xencor in the first quarter worth $24,557,000. Logos Global Management LP boosted its holdings in shares of Xencor by 130.8% in the 2nd quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock valued at $28,395,000 after buying an additional 850,000 shares during the period. Point72 Asset Management L.P. grew its position in shares of Xencor by 52.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,261,789 shares of the biopharmaceutical company’s stock valued at $23,886,000 after buying an additional 436,389 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Xencor by 9.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock worth $84,530,000 after acquiring an additional 335,881 shares during the period. Finally, Baker BROS. Advisors LP lifted its holdings in Xencor by 122.2% in the first quarter. Baker BROS. Advisors LP now owns 545,431 shares of the biopharmaceutical company’s stock worth $12,070,000 after acquiring an additional 300,000 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on XNCR shares. BMO Capital Markets reissued an “outperform” rating and set a $34.00 price target (up previously from $32.00) on shares of Xencor in a research note on Friday, November 8th. Wedbush reissued an “outperform” rating and issued a $38.00 target price on shares of Xencor in a report on Thursday, November 7th. Royal Bank of Canada boosted their price objective on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research report on Thursday, September 26th. Finally, JPMorgan Chase & Co. raised their target price on shares of Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.75.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.